Saxagliptin Cardiovascular Safety Affirmed, But Is It Approvable...And When?
Executive Summary
The prospects for approval of Bristol-Myers Squibb/AstraZeneca's saxagliptin by its user fee goal date of April 30 seem remote at best
You may also be interested in...
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?
Large outcomes studies showed neither cardiovascular harm nor benefit with BMS/AstraZeneca’s saxagliptin or Takeda’s alogliptin, prompting some commenters to question whether FDA’s blanket approach to CV safety for all antidiabetic agents needs adjustment.
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
There is one message that sponsors should take to heart from an FDA advisory committee's first pass at applying new cardiovascular outcomes standards to type 2 diabetes medicines: enroll sicker patients in pivotal trials
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
There is one message that sponsors should take to heart from an FDA advisory committee's first pass at applying new cardiovascular outcomes standards to type 2 diabetes medicines: enroll sicker patients in pivotal trials